YYYong-Hua Yu

Yong-Hua Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yong-Hua Yu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Yong Zhang

    Shandong First Med Univ, Shandong Canc Hosp & Inst, Dept Abdominal Radiat Oncol Ward 2, Canc Hosp, 440 Ji Yan Rd, Jinan 250117, Peoples R China

    3 shared publications
  • Jin-Ming Yu

    Shandong Acad Med Sci, Dept Radiat Oncol, Jinan, Peoples R China

    2 shared publications
  • Zhen Xu

    Shandong First Med Univ, Shandong Canc Hosp & Inst, Canc Hosp, Jinan, Peoples R China

    2 shared publications
  • Baosheng Li

    Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China

    1 shared publication
  • Changsheng Cong

    Shandong Tumor Hospital

    1 shared publication
  • Da-Li Han

    Shandong Acad Med Sci, Dept Radiat Oncol, Jinan, Peoples R China

    1 shared publication

Latest Publications

  • Open Access

    Successful treatment of advanced alveolar soft part sarcoma with camrelizumab combined with apatinib: a case report

    by Zhen Xu, Yong Zhang, Yong-Hua Yu

    Alveolar soft part sarcoma (ASPS) is a rare and highly malignant mesenchymal tumor that primarily affects adolescents and young adults. ASPS is characterized by a slow growth rate, high metastatic potential, and resistance to conventional therapies. The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced malignancies, improving the objective response rate (ORR) and prolonging patient survival. The combination of immunotherapy with targeted therapies can overcome resistance to treatment with ICIs alone. Although substantial progress has been made in various solid tumors, the clinical relevance of ICIs, used alone or in combination with other therapies, in patients with ASPS remains unclear. This is a case report of a 32-year-old man who was diagnosed with advanced ASPS. After 8 months of anlotinib treatment, the patient's disease progressed and new cerebellar metastases were detected. Radiotherapy was administered in addition to camrelizumab combined with apatinib to treat the brain metastases. The patient achieved partial remission (46%) after 3 months of treatment and did not present any severe side effects. This is the first reported case of the successful treatment of advanced ASPS with camrelizumab combined with apatinib. This case supports the use of a novel treatment regimen for patients with inoperable ASPS or ASPS that is resistant to conventional therapies.


  • Open Access

    Primary giant cell malignant fibrous histiocytoma of the lung: a rare case report and literature review

    by Zhen Xu, Wei Qu, Yonghua Yu

    Malignant fibrous histiocytoma (MFH) usually involves the extremities. Among MFH, primary giant cell malignant fibrous histiocytoma of the lung is extremely rare, with nonspecific symptoms. A 45-year-old woman was first diagnosed as sclerosing hemangioma due to long-term persistent cough and blood in sputum. One year later, the condition became worse and hemoptysis occurred. At the second visit, the same mass was found to be larger than the previous one. Lobectomy was performed and the primary giant cell MFH of the lung was confirmed. Renal and sacrum metastasis occurred six months after operation. The efficacy of hypofractionation radiotherapy and immuno targeted follow-up therapy is significant. At present, there is no standard treatment plan. For the patients in the early stage, surgical resection is the main treatment method; but for the patients in the middle and late stage, the treatment is relatively single. So early diagnosis and treatment are particularly important, In this paper, we first report the use of pembrolizumab combined with anlotinib in a patient with advanced giant cell MFH of the lung, with failure of routine treatment. The development of the disease had successfully delayed and satisfactory results were observed. Therefore, it is very necessary to emphasize the choice of treatment plan to improve the prognosis of patients.


  • Nanomaterials for Combinational Radio–Immuno Oncotherapy

    by Juan Wang, Zhongmin Li, Zhongtang Wang, Yonghua Yu, Di Li, Baosheng Li, Jianxun Ding

    Radiotherapy, a clinically used local treatment modality of cancers, is regarded as a promising candidate to promote current immunotherapy through initiating an in situ vaccination effect and reprogramming the immunosuppressive microenvironment. The combination of radiotherapy and immunotherapy, referred to as combinational radio–immuno oncotherapy (CRIOT), elicits a synergistic antitumor effect based on the immunomodulatory properties of radiation. Unfortunately, current CRIOT accompanies low response rate and severe toxicity in clinical trials, thus limiting its application. To this end, various nanomaterials are being developed to sensitize radiotherapy or deliver immune agents, or both, to improve the unsatisfactory outcomes of CRIOT. Herein, enhanced antitumor efficacy of CRIOT with nanomaterials through the possible mechanisms of rejuvenation and activation of T cells, increased presentation of tumor‐related antigens, and inhibition of suppressive macrophages is presented, and the prospect of CRIOT in clinical practice is proposed.


  • Open Access

    FDG PET-CT in Non-small Cell Lung Cancer: Relationship between Primary Tumor FDG Uptake and Extensional or Metastatic Potential

    by Shou-Hui Zhu, Yong Zhang, Yong-Hua Yu, Zheng Fu, Lei Kong, Da-Li Han, Lei Fu, Jin-Ming Yu, Jia Li

    Objective: To explore the relationships between primary tumor F-18-FDG uptake measured as the SUVmax and local extension, and nodal or distant organ metastasis in patients with NSCLC on pretreatment PET-CT. Methods: 93 patients with NSCLC who underwent F-18-FDG PET-CT scans before the treatment were included in the study. Primary tumor SUVmax was calculated; clinical stages, presence of local extension, nodal and distant organ metastases were recorded. The patients with SUVmax >= 2.5 were divided into low and high SUVmax groups by using the median SUVmax. The low SUVmax group consisted of 45 patients with SUVmax= 10.5. Their data were compared statistically. Results: 91 cases with SUVmax >= 2.5 were included for analysis. The mean SUVmax in patients without any metastasis was 7.42 +/- 2.91 and this was significantly lower than that (12.18 +/- 4.94) in patients with nodal and/or distant organ metastasis (P=0.000). In the low SUV group, 19 patients had local extension, 22 had nodal metastasis, and 9 had distant organ metastasis. In the high SUV group, 31 patients had local extension, 37 had nodal metastasis, and 18 had distant organ metastases. There was a significant difference in local extension (P =0.016), distant organ metastasis (P =0.046), and most significant difference in nodal metastasis rate (P =0.002) between the two groups. In addition, there was a moderate correlation between SUVmax and tumor size (r = 0.642, P<0.001), tumor stage (r = 0.546, P<0.001), node stage (r = 0.388, P<0.001), and overall stage (r = 0.445, P= 0.000). Conclusion: Higher primary tumor SUVmax predicts higher extensional or metastatic potential in patients with NSCLC. Patients with higher SUVmax may need a close follow-up and more reasonable individual treatment because of their higher extensional and metastatic potential.